Alan Ezrin, PhD

Twitter LinkedIn

Prior to joining NX PharmaGen, Dr. Ezrin served as Director and CEO of Bradmer Pharmaceuticals Inc [TSX: BMR], guiding the company’s transfer of its lead brain cancer drug technology from Duke University and the launch of a landmark Phase III trial with that drug. In his role, Dr. Ezrin served as the primary strategic liaison to the FDA, to key vendors, to investors and equity analysts, and to the pre-eminent physicians in the field. Prior to joining Bradmer, Dr. Ezrin served as a Director and Chief Scientific Officer of Cardiome Pharma Corp. [TSX:COM, NASDAQ:CRME], where he played an integral role in the development of the company’s lead drug candidate from early stage clinical trials through strategic partnership and NDA filing. Dr. Ezrin has more than 27 years of experience in research and business development in both the pharmaceutical and biotechnology sectors in the US and Canada. Dr. Ezrin was with Sterling-Winthrop Research Group from 1982 to 1993, after which he joined Glycomed Inc. as Assistant Vice President of Experimental Therapeutics. In 1995, he joined RedCell Inc. as Vice President of Pre-Clinical Development leading to the restructuring of the firm in 1997 through the creation of ConjuChem Inc. At ConjuChem, Dr. Ezrin served as Chief Operating and Scientific Officer. He joined Cardiome Pharma Corp. in 2001 as its Chief Scientific Officer and played a vital role in the successful evolution of the firm to a leading cardiovascular company listed on the TSX and NASDAQ exchanges. Dr. Ezrin is extensively published in numerous scientific journals and holds numerous patents for inventions in the pharmaceutical industry. In addition, he has raised substantial invested capital and facilitated numerous transactions and partnerships in the biotech sector.